Kate V Meriwether1, Rebecca G Rogers2, Ellen Craig2, Sean D Peterson3, Robert E Gutman4, Cheryl B Iglesia4. 1. Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM. Electronic address: meriwet2@salud.unm.edu. 2. Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM. 3. University of New Mexico School of Medicine, Albuquerque, NM. 4. Departments of Obstetrics and Gynecology and Urology, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Abstract
OBJECTIVE: Pessaries are important options for women with pelvic floor disorders, but many pessary users experience bacterial vaginosis (BV). The aim of this study was to evaluate the effect of TrimoSan gel (Milex Pessaries, Cooper Surgical, Trumbull, CT) on BV prevalence among pessary users. STUDY DESIGN:Women presenting for a pessary fitting completed questionnaires on vaginal symptoms and hormone therapy use and underwent aBV BLUE test and slide collection for BV analysis by Nugent's criteria. Following pessary fitting, women were randomized to either standard pessary care with the use of TrimoSan placed vaginally twice weekly or to standard pessary care without TrimoSan gel. Women returned 2 weeks and 3 months later for a repeat slide collection for Gram stain, BV BLUE testing, and completion of questionnaires on vaginal symptoms and desire to continue the pessary. RESULTS: There were 184 women randomized after successful fitting (92 to the TrimoSan group), and 147 (79%) presented for 3-month follow up. Mean age was 56 ± 16 years; patients were mostly white (57%) or Hispanic (23%), and 36% were using hormone therapy. The groups did not differ in the prevalence of BV by Nugent's criteria at 2 weeks (20% TrimoSan vs 26% no gel, P = .46) or 3 months (24% TrimoSan vs 23% no gel, P = .82), nor did they differ in BV by BV BLUE testing at 2 weeks (0% TrimoSan vs 4% no gel, P = .12) or 3 months (3% TrimoSan vs 0% no gel, P = .15). The prevalence of at least one vaginal symptom did not differ between groups at 2 weeks (44% TrimoSan vs 45% no gel, P = .98) or 3 months (42% TrimoSan vs 32% no gel, P = .30). The TrimoSan group was equally likely to want to continue their pessary use compared with the standard care group at 2 weeks (90% vs 86%, P = .64) and 3 months (63% vs 60%, P = .76). CONCLUSION:TrimoSan gel in the first 3 months of pessary use does not decrease the prevalence of BV or vaginal symptoms and does not alter the likelihood of a woman desiring to continue pessary use.
RCT Entities:
OBJECTIVE: Pessaries are important options for women with pelvic floor disorders, but many pessary users experience bacterial vaginosis (BV). The aim of this study was to evaluate the effect of TrimoSan gel (Milex Pessaries, Cooper Surgical, Trumbull, CT) on BV prevalence among pessary users. STUDY DESIGN:Women presenting for a pessary fitting completed questionnaires on vaginal symptoms and hormone therapy use and underwent a BV BLUE test and slide collection for BV analysis by Nugent's criteria. Following pessary fitting, women were randomized to either standard pessary care with the use of TrimoSan placed vaginally twice weekly or to standard pessary care without TrimoSan gel. Women returned 2 weeks and 3 months later for a repeat slide collection for Gram stain, BV BLUE testing, and completion of questionnaires on vaginal symptoms and desire to continue the pessary. RESULTS: There were 184 women randomized after successful fitting (92 to the TrimoSan group), and 147 (79%) presented for 3-month follow up. Mean age was 56 ± 16 years; patients were mostly white (57%) or Hispanic (23%), and 36% were using hormone therapy. The groups did not differ in the prevalence of BV by Nugent's criteria at 2 weeks (20% TrimoSan vs 26% no gel, P = .46) or 3 months (24% TrimoSan vs 23% no gel, P = .82), nor did they differ in BV by BV BLUE testing at 2 weeks (0% TrimoSan vs 4% no gel, P = .12) or 3 months (3% TrimoSan vs 0% no gel, P = .15). The prevalence of at least one vaginal symptom did not differ between groups at 2 weeks (44% TrimoSan vs 45% no gel, P = .98) or 3 months (42% TrimoSan vs 32% no gel, P = .30). The TrimoSan group was equally likely to want to continue their pessary use compared with the standard care group at 2 weeks (90% vs 86%, P = .64) and 3 months (63% vs 60%, P = .76). CONCLUSION:TrimoSan gel in the first 3 months of pessary use does not decrease the prevalence of BV or vaginal symptoms and does not alter the likelihood of a woman desiring to continue pessary use.
Authors: Minita S Patel; Colleen Mellen; David M O'Sullivan; Christine A Lasala Journal: Female Pelvic Med Reconstr Surg Date: 2011-11 Impact factor: 2.091
Authors: Nirmala Chandralega Kampan; Seri Suniza Suffian; Nur Suhaini Ithnin; Marlyn Muhammad; Syed Zulkifli Syed Zakaria; Muhammad Abdul Jamil Journal: Sex Reprod Healthc Date: 2010-11-18
Authors: Jennifer M Wu; Camille P Vaughan; Patricia S Goode; David T Redden; Kathryn L Burgio; Holly E Richter; Alayne D Markland Journal: Obstet Gynecol Date: 2014-01 Impact factor: 7.661
Authors: Jeffrey L Clemons; Vivian C Aguilar; Tara A Tillinghast; Neil D Jackson; Deborah L Myers Journal: Am J Obstet Gynecol Date: 2004-04 Impact factor: 8.661
Authors: Kate V Meriwether; Yuko M Komesu; Ellen Craig; Clifford Qualls; Herbert Davis; Rebecca G Rogers Journal: J Sex Med Date: 2015-12-03 Impact factor: 3.802
Authors: Nicole J Fregosi; Deslyn T G Hobson; Casey L Kinman; Jeremy T Gaskins; J Ryan Stewart; Kate V Meriwether Journal: Female Pelvic Med Reconstr Surg Date: 2018 Mar/Apr Impact factor: 2.091